The monoclonal antibody, gemtuzumab ozogamicin, has been used successfully as a treatment for APL.,[10] although it has been withdrawn from the US market due to concerns regarding potential toxicity of the drug and it is not currently marketed in Australia, Canada or the UK.[10][11] It given in conjunction with ATRA produces a response in around 84% of patients with APL, which is comparable to the rate seen in patients treated with ATRA and anthracycline-based therapy.[10] It produces less cardiotoxicity than anthracycline-based treatments and hence may be preferable in these patients.[10]